Antibody-mediated inhibition of syndecan-4 dimerisation reduces interleukin (IL)-1 receptor trafficking and signalling.
Lars GodmannMiriam BollmannAdelheid Korb-PapUlrich KönigJoanna SherwoodDenise BeckmannKatja MühlenbergFrank EchtermeyerJames WhitefordGiulia De RossiThomas PapJessica BertrandPublished in: Annals of the rheumatic diseases (2020)
Collectively, our data suggest that Ab that specifically inhibit sdc4 dimerisation may support anti-IL-1 strategies in diseases such as inflammatory arthritis.